Post on 16-Mar-2019
ABERDEEN PROVING
GROUND
ADVANCED PLANNING
BRIEFING TO INDUSTRY
Joint Project Management Office for
Medical Countermeasure Systems
Presented by: COL David P. Hammer 2 FEB 2017
The forecast data is for planning purposes, does not represent a pre-
solicitation synopsis, does not constitute an invitation for bid or request for
proposal, and is not a commitment by the government to purchase the desired
products and services
PROGRAM OVERVIEW
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITIES
Joint Vaccine Acquisition Program
• Marburg Vaccine
• Western, Eastern, and Venezuelan Equine Encephalitis Virus Vaccine
Biological Defense Therapeutics
• Antiviral Therapeutic Prototype
• Anti-Alphavirus Therapeutic Prototype
• Antibacterial Therapeutic Prototype
Chemical Defense Pharmaceuticals
• Improved Nerve Agent Treatment System (INATS) Improved Oxime Treatment Increment
• Expansion of Autoinjector Manufacturing Base – Dual Drug Delivery Device (D4)
Diagnostics
• Next Generation Diagnostics System Increment 2 Platform Component Development
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
ABERDEEN PROVING
GROUND
ADVANCED PLANNING
BRIEFING TO INDUSTRY
Joint Project Manager for Medical Countermeasure Systems
Joint Vaccine Acquisition Program (JVAP)
The forecast data is for planning purposes, does not represent a pre-
solicitation synopsis, does not constitute an invitation for bid or request for
proposal, and is not a commitment by the government to purchase the desired
products and services
PROGRAM OVERVIEWMedical Countermeasures Systems (MCS) mission area
is the development, production and fielding of medical solutions to counter Chemical, Biological, Radiological and Nuclear threats.
Within MCS, the Joint Vaccine Acquisition Program (JVAP) has the mission to develop, produce and field FDA–licensed biological defense vaccines.
Current JVAP portfolio includes vaccines for protection against Filoviruses, Equine Encephalitis viruses (western, eastern and Venezuelan) Botulinum Toxins (serotypes A and B), Ricin toxin and pneumonic Plague.
Future focus areas include vaccines for protection against Francisella tularensis, Coxiella burnetii (Q-Fever), and Burkholderia
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITYTITLE: • Marburg Vaccine to Protect Against Aerosolized Marburg Virus
GOAL:• Development of multiple Marburg Vaccine Prototypes Against Aerosolized Marburg
Virus through a Phase 1 clinical trial
PROGRAM OFFICE CONTACT: Chris DorseyMCS-JVAPChristopher.b.dorsey2.civ@mail.mil
CONTRACT OFFICE CONTACT:Alexandra Trunzo,Contract Specialistalexandra.m.trunzo.civ@mail.mil
JVAP intends to meet this requirement through a competitive award through the OTA Consortium.
– RPP release anticipated in Feb 2017– Award anticipated April 2017– Period of performance expected to be through Phase 1 clinical trials– Scope will include all manufacturing efforts, non-clinical studies and regulatory
efforts required to support execution of a phase 1 clinical trial
JVAP intends to competitively award a follow on contract for all activities leading to FDA licensure starting in early 2020
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITYTITLE: • Western, Eastern, and Venezuelan Equine Encephalitis Virus Vaccine to Protect Against
Aerosolized exposure to above alphaviruses
GOAL:• Development of an multiple-target single-vector Vaccine Prototype Against Aerosolized
Equine Encephalitic viruses including Venezuelan Equine Encephalitis Virus through a Phase 1 clinical trial
PROGRAM OFFICE CONTACT: • Andrew Glenn
MCS-JVAPAndrew.m.glenn7.civ@mail.mil
CONTRACT OFFICE CONTACT:• Alexandra Trunzo,
Contract Specialistalexandra.m.trunzo.civ@mail.mil
JVAP intends to meet this requirement through a competitive award through the OTA Consortium.
– RPP release anticipated in Feb 2017– Award anticipated April 2017– Period of performance expected to be through Phase 1 clinical trials– Scope will include all manufacturing efforts, non-clinical studies and regulatory efforts
required to support execution of a phase 1 clinical trial
JVAP intends to competitively award a follow on contract for activities leading to FDA licensure starting in early 2020
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
ABERDEEN PROVING
GROUND
ADVANCED PLANNING
BRIEFING TO INDUSTRY
Joint Project Manager for Medical Countermeasure Systems
Biological Defense Therapeutics (BDTX)
The forecast data is for planning purposes, does not represent a pre-
solicitation synopsis, does not constitute an invitation for bid or request for
proposal, and is not a commitment by the government to purchase the desired
products and services
PROGRAM OVERVIEW
JPM-MCS-BDTX has provided a broad Statement of Objectives (SOO) for a consortium Other Transactional Authority (OTA) solicitation and the MCS Broad Agency Announcement (BAA), for therapeutics against Biological Warfare Agents (BWAs)
Viral Threats: Filoviridae (Zaire ebolavirus, Sudan ebolavirus, Marburg marburgvirus, Tai Forest, and Bundibugyo); Alphaviridae (Eastern Equine Encephalitis, Western Equine Encephalitis, Venezuelan Equine Encephalitis); Bunyaviridae (Hantaan)
Bacterial Threats: Bacillus anthracis (Anthrax), Brucellaspp. (Brucellosis), Burkholderia mallei (Glanders), Burkholderia pseudomallei (Meliodosis), Francissilatularensis (Tularemia); Yersinia pestis (Plague)
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITYTITLE: Antiviral Therapeutic Request for Prototype Project
CONTRACT TYPE: CPIF/CPFF
(to be awarded via OTA W15QKN-16-9-1002)
ESTIMATED VALUE: <$240M
CONTRACTING CONTACT:
ACC-NJJim Cummiskey973.724.7278james.p.cummsikey4.civ@mail.mil
Solicitation #: MCDC-RPP-17-01
ESTIMATED SOLICITATION RELEASE DATE: 2QFY17
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITYTITLE: Anti-Alphavirus Therapeutic Request for Prototype
Project
CONTRACT TYPE: CPIF/CPFF
(to be awarded via OTA W15QKN-16-9-1002)
ESTIMATED VALUE: <$240M
CONTRACTING CONTACT:
ACC-NJJim Cummiskey973.724.7278james.p.cummsikey4.civ@mail.mil
Solicitation #: MCDC-RPP-17-01
ESTIMATED SOLICITATION RELEASE DATE: 2QFY17
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITYTITLE: Antibacterial Therapeutic Request for Prototype Project
CONTRACT TYPE: CPIF/CPFF
(to be awarded via OTA W15QKN-16-9-1002)
ESTIMATED VALUE: <$100M
CONTRACTING CONTACT:
ACC-NJ
Jim Cummiskey
973.724.7278
james.p.cummsikey4.civ@mail.mil
SOLICITATION #: MCDC-RPP-17-01
ESTIMATED SOLICITATION RELEASE DATE: 2QFY17
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Dr. Erin Reichert2 February 2017
Aberdeen proving ground
advanced planning briefing to
industry
CBM Mission
Medical S&T Division is responsible for ensuring robust
pipelines of vaccine and therapeutic candidates that can be
transitioned and matured into products by our advanced
development partners. This directly supports the overall
enterprise goal of developing and delivering novel medical
technologies to address current and emerging biological
threats in order to protect the lives and maintain the battle
readiness of our warfighters.
Bio-Pretreatments Branch
Discovery and development of vaccines
for: alphaviruses, filoviruses, Bacillus
anthracis (anthrax), Burkholderia mallei
(glanders), Burkholderia pseudomallei
(meliodosis), Francisella tularensis
(tularemia), Coxiella burnetii (Q Fever),
and botulinum, ricin and SEB toxin
Bio-Therapeutics Branch
Discovery and development of
therapeutics for alphaviruses,
filoviruses, botulinum toxin, and broad-
spectrum antibiotics targeting multi-drug
resistant bacterial threat pathogens
J9 CBM Focus Areas
Supporting S&T
Investments in animal model development, novel manufacturing technologies that
exploit readily adaptable expression platforms and leverage flexible
biomanufacturing technologies, understanding host-pathogen/toxin interaction for
identification of targets and/or biomarkers, adjuvants and stabilization
technologies, drug delivery methods, and compound library compilation and
characterization
Biological Prophylaxis &
Pretreatment
Core Capability Concept
Provide the warfighter protection against biowarfare agents through the administration of prophylactic pre- and post-exposure vaccines and mAbsagainst known bacterial, viral and toxin threats
JSTO Deliverables
Near-Term• rVSV-ZEBOV, also MARV and SUDV
• WEVEE DNA vaccine
• B. anthracis capsule conjugate
• Botulinum toxin mAbs
Mid-Term• Burkholderia OMV and CRM
conujugate
• Live-attenuated Francisella
• Ricin subunit vaccine
Far-Term• T Cell-based Q-fever vaccine
• Informatics-informed next
generation vaccines
• On-demand prophylaxis
Capability
Provide advanced prophylactic MCMs to protect the warfighter against loss of morbidity and
mortality due to live biological and biotoxin threats
16
Viruses
• Hemorrhagic Fever Viruses – Ebola & Marburg
• Encephalitic Alphaviruses – EEEV, VEEV,
WEEV
Toxins• Ricin
• BoNt
• SEB
Bacteria
• Bacillus anthracis
• Francisella tularensis
• Burkholderia mallei /pseudomallei
• Coxiella burnetii
• Yersinia pestis
Focus Agents Current Approaches
Vaccines – Current Approach
• Animal model development
• Basic research into host-pathogen/toxin interaction
• Stabilization technologies
Enabling Technologies
• Protein Subunit
• Bacterial vector platforms
• Live Attenuated
• Virus Like Particles
• DNA vaccine
• Viral vectored vaccine
• Protein Subunit
• mAbs
Core Capability Concept
Provide the warfighter protection against biowarfare agents through the post-exposure administration of therapeutics against known bacterial, viral and toxin threats of interest and emerging infectious threats
Capacity
Discovery and development of therapeutic countermeasures to protect the warfighter against
biological and biotoxin threats
Far-Term• Utilization of predictive models
• Drugs employing nontraditional
antibacterial modalities
Biological Therapeutics
JSTO Deliverables
Mid-Term• SMI/improved pan filo and pan alpha
virus therapies
• Small-molecule therapeutics against
novel bacterial targets
Near-Term• Panfilovirus mAb cocktail
• Alphavirus mAb cocktail
• Repurposed antibiotics for BW threats
• Botulinum Toxin SMI
18
Viruses• Filoviruses (Ebola, Marburg) and
hemorrhagic fever viruses
• Encephalitic Alphaviruses VEEV, EEEV,
WEEV
Toxins
• Botulinum Toxin
Bacteria
• Burkholderia spp.
• Bacillus anthracis
• Francisella tularensis
• Yersina pestis
Focus Agents
• Novel therapeutic approaches
• Host-directed & agent-based
• Antibiotic potentiation
• Circumvent/address resistance
• FDA-approved drug repurposing
• Novel therapeutic approaches
• Host-directed & agent-based
• Novel mAb treatments
• Repurposing of FDA-approved drugs
Approach
• Small molecule therapeutics
• Repurposing of FDA-approved drugs
Therapeutics – Current Approach
• Animal and other predictive models • Novel manufacturing technologies • Protein stabilization technologies
• Controlled drug delivery technologies • Novel formulation and dosing methods• PB-PK-PD toolbox • Regulatory Science
• Basic research into host-pathogen/toxin interactions for identification of new targets and/or biomarkers
Enabling Technologies
ABERDEEN PROVING
GROUND
ADVANCED PLANNING
BRIEFING TO INDUSTRY
Joint Project Manager for Medical Countermeasure Systems
Chemical Defense Pharmaceuticals (CDP)
The forecast data is for planning purposes, does not represent a pre-
solicitation synopsis, does not constitute an invitation for bid or request for
proposal, and is not a commitment by the government to purchase the desired
products and services
PROGRAM OVERVIEW
Improved Nerve Agent Treatment System (INATS)
– Family of Systems to provide FDA-approved improved oxime to be used in conjunction with Atropine in a combined autoinjector delivery system
• Improved Oxime Treatment Increment
– To replace 2-PAM with a medical countermeasure that will provide treatment to a broad spectrum of traditional nerve agents and emerging threats
• Expanded Indication for Pyridostigmine Bromide (PB) Increment
– Complementary to Improved Oxime Treatment Increment
– FDA approval for use beyond Soman; for additional traditional nerve agents and emerging threats
• Increased Survival Increment
– Complementary adjunct to Improved Oxime Treatment Increment
– A centrally‐acting (CA) therapeutic to increase survival
Expansion of Autoinjector Manufacturing Base – Dual Drug Delivery Device (D4) project
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITY
TITLE: Improved Nerve Agent Treatment System (INATS),
Improved Oxime Treatment Increment
CONTRACT TYPE: This opportunity will be submitted to the MCS
OTA Consortium
ESTIMATED VALUE: $40M-$60M
CONTRACTING CONTACT: ACC-New Jersey/Picatinny E.
Blancuzzi, kimberly.e.blancuzzi.civ@mail.mil; (973) 724-2200
SOLICITATION #: TBD
ESTIMATED SOLICITATION RELEASE DATE: 1QFY18 –
2QFY18
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITY
TITLE: Expansion of Autoinjector Manufacturing Base – Dual Drug
Delivery Device (D4) project
CONTRACT TYPE: This opportunity has been submitted to the
MCS OTA Consortium, and is currently undergoing the RPP
process
ESTIMATED VALUE: $10-30M
CONTRACTING CONTACT: NCBDC Consortium Management
Firm, ATI, Attn: Ms. Mica Dolan, 315 Sigma Drive, Summerville,
SC 29486, E-mail mica.dolan@scra.org
SOLICITATION #: RPP 16-02, Subobjective Area (TRE-16-03)
ESTIMATED AWARD DATE: 2QFY17
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Dr. Alison Director-Myska2 February 2017
Aberdeen proving ground
advanced planning briefing to
industry
UNCLASSIFIED
UNCLASSIFIED
J9CBS Advanced & Emerging Threat
Chemical Medical
Countermeasures (MCMs)
Deliver novel medical concepts and
technologies (i.e. pretreatments &
therapeutics) to address current
and emerging chemical threats to
protect the lives of our warfighters.
CB Research Center of
Excellence
Provide capabilities and
competency to the DoD labs
through the DTRA Fellowship
program, explore collaborative
opportunities, and recruit and
mentor young talent through
scholarly programs (e.g. STEM
and NRC Post doc).
Mission: Develop and transition novel concepts and technologies to address current and emerging threats to protect the lives of our warfighters
Provide rapid validated chemical
and biological agent property and
reactivity data and determine
toxicological mechanisms to
inform risk assessment.
Threat Agent Science (TAS)
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
Nerve Agent Prophylaxis &
Pretreatments
Core Capability Concept
Provide protection through the administration of broad spectrum MCMs to the Warfighter against the adverse effects of organophosphorus (OP)–based Chemical Warfare Agents (CWA) either prior to or post-exposure, but before presentation of symptoms
JSTO Objectives
Near-Term• Alternative manufacturing process
• Technologies for expressing prophylactic enzymes in vivo
• FDA-approved drugs
• Animal models to support FDA approval
Mid-Term• Technologies for expressing prophylactic enzymes in vivo
• FDA-approved drugs
• Animal models to support FDA approval
Prophylaxis
Capability
Provide advanced MCMs to prolong Force strength and capability against the effects of a broad spectrum of
organophosphorus (OP)–based Chemical Warfare Agents (CWA)
26
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
Core Capability Concept
Provide increased CNS penetration of MCM regimen to improve the therapeutic effectiveness against organophosphorus (OP)–based Chemical Warfare Agents (CWA)• Adjuncts to existing regimen• Substitutions for parts of existing regimen• Alternatives to existing regimen
Capability
Provide centrally-acting Medical Countermeasures (MCMs) therapeutics for increased survival, reduced
morbidity and decreased neurological damage when used as part of an MCM regimen against
organophosphorus (OP)–based Chemical Warfare Agents (CWA)
Nerve Agent Therapeutics
27
JSTO Objectives
Near-Term• Protection of the central nervous system against
organophosphorus (OP) chemical warfare agents
(CWAs).
• Broad spectrum cholinesterase reactivators
• FDA-approved drugs against a range of priority chemical
threats
• Animal models to enable FDA approval
Mid-Term• FDA-approved drugs against a range of priority chemical
threats
• Animal models to enable FDA approval
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
Capability
Provide effective medical countermeasure (MCM) against Emerging Chemical Threats
Emerging Threats
28
Core Capability Concept
Develop and utilize representative animal models to evaluate and exploit FDA-approved drugs against DoD emerging chemical threats needs to provide MCM advice and options to the warfighter.
JSTO Objectives
Near-Term• Assess FDA-approved drugs against a specific class of
Emerging Chemical Threat
• Develop Human equivalent dosing of MCM against
compounds of interest
Mid-Term• Assess FDA-approved drugs against a range of priority
chemical threats
• Establish human equivalent dosing of MCM against likely
threats and recommended path forward
HOW IT WORKS:
Identification of threat agent Screen currently available
drugs as MCM
Determine efficacy of MCM
against threat agent
Transition
Information
packet
CONOPS
UNCLASSIFIED
UNCLASSIFIED
Personnel / Patient
Decontamination
29
Core Capability Concept
Develop effective therapeutic strategies to minimize cutaneous tissues injuries from exposure to chemical warfare agents (CWAs) and decrease adverse dermal effects resulting from injuries to lingering CWA reservoirs.
Capability
Provide effective therapeutic strategies to minimize or ameliorate cutaneous tissue injuries resulting from
exposure to chemical warfare agents (CWAs)
Challenges• Shelf life stability (years not
months)
• Multi-Agent efficacy
• Neutralizes agent, non-toxic to
patient
Effort• Understanding cutaneous absorption
and reservoir effect
• Developing novel dermal therapeutic
and/or decontamination compounds
and methods of application
Issue• Current formulations are only
approved by the FDA for small
area applications on intact skin
• Life-cycle costs
• Desire for ocular and wound
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
ADMET CoE
• Utilizes pharmaceutical industry-standard Test
and Evaluation (T&E) and Modeling and
Simulation (M&S) protocols,
• Supports the pre-Milestone A determination of
MCM technical maturity for the Chemical
Biological Defense Program (CBDP), and
• Provides life-cycle benefits in cost, schedule
and performance to the MCM portfolio by
reducing risk.
The Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Center of Excellence
(CoE) partnership with DoD laboratories enhances the successful development of novel medical
countermeasures (MCMs)
30
EXCRETION
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
Opportunities
• Current:• Fundamental Research to Counter Weapons of Mass
Destruction
• Solicitation Number: HDTRA1-14-24-FRCWMD-BAA
• Estimated value: Up to $1M/yr
• Contracting contact: TBD
• Future:• Chemical/Biological Technologies Program Build
DTRA BAA
• MCS OTA Consortium
• Combating Weapons of Mass Destruction (CWMD) Research and Technology Development ID/IQ
31
ABERDEEN PROVING
GROUND
ADVANCED PLANNING
BRIEFING TO INDUSTRY
Joint Project Manager for Medical Countermeasure Systems
Diagnostics (DX)
The forecast data is for planning purposes, does not represent a pre-
solicitation synopsis, does not constitute an invitation for bid or request for
proposal, and is not a commitment by the government to purchase the desired
products and services
PROGRAM OVERVIEW
Next Generation Diagnostics System Increment 2 (NGDS Inc 2) will provide a set of affordable and supportable materiel solutions to address CBRN diagnostics
NGDS Inc 2 is part of a Family of Systems approach
– Seeking complementary diagnostic capability with NGDS Inc 1 PCR analyzer (FilmArray)
– Near term mature solutions for CBRN diagnostics that would add value to treatment decisions
– Considering platform development effort that could address a broad range of CBRN threats and diagnostic approaches, to include host response biomarkers
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
OPPORTUNITYTITLE: Next Generation Diagnostics System Increment 2
Platform Component Development
CONTRACT TYPE: FFP/CPFF*
ESTIMATED VALUE: $40M-$60M
CONTRACTING CONTACT: ACC-Natick Jessica Ely301-619-8457Jessica.l.ely.civ@mail.mil
SOLICITATION #: TBD
ESTIMATED SOLICITATION RELEASE DATE: Draft release
2QFY19
* The above opportunity will be considered for inclusion under
the upcoming MCS OTA Consortium effort
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
HOW TO JOIN MEDICAL CBRN
DEFENSE CONSORTIUM (MCDC) • Visit: www.medcbrn.org
• Complete and sign Membership Application
• Review and sign Articles of Collaboration
• Provide DD2345 Certificate Number
• Military Critical Technical Data Agreement
• To obtain access to unclassified technical data
• If operating under Foreign Ownership, Control or
Influence (FOCI)
• DSS-approved mitigation plan OR signed
Export Compliance Acknowledgement Form
Send to MCDC@ati.org
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Chemical and Biological
Technologies Department (J9CB)
Defense Threat Reduction Agency & USSTRATCOMCenter for Combating WMD & Standing Joint Force
Headquarters-Elimination
Advanced Planning Briefing to Industry
UNCLASSIFIED
UNCLASSIFIED
Medical Diagnostics
37
Near-term:
• Host-based biomarker discovery in blood and other clinical relevant matrices.
• Diagnostic assays for emerging threat agents (refining and developing novel assay designs).
• Biomedical informatics tools and applications (genomic/clinical bioinformatics).
• Rapid multiplex low-cost actionable assays.
• Enabling technologies for wearable threat exposure warning.
• Orthogonal diagnostic platforms and CLIA-waivable point-of-care devices.
• Sample collection, stabilization, transport, and preparation technologies.
• Expand biological warfare agent diagnostics for NGDS increment 2.
Mid-term:
• Diagnostics for host-based biomarkers from blood and/or other clinical matrices.
• Rapid and innovative diagnostic assays for emerging threat agents and antimicrobial resistance microbes.
• Diagnostics using high-throughput sequencing technologies.
UNCLASSIFIED
UNCLASSIFIED
Basic Research BAA Solicitation:
HDTRA1-11-21-BRCWMD-BAA
38
• In effect March 2011-September 2021
• Typically multiple opening & closing periods, with at least one annual opportunity solicited
by an Amendment to the BAA posted to Grants.gov in early December
• However, with the transition of the DTRA Basic Research Program to the Office of the Chief
Scientist, a consolidation of solicitations is taking place to streamline processes and to
present a single opportunity to the university-centric research community
• This transition began with the December 1, 2016 publication of FY2018 Basic Research
Topics within the Fundamental Research BAA, HDTRA1-14-24-FRCWMD-BAA (see next
slide)
• The Basic Research BAA Solicitation is valid for use through September 2021 should the
Office of the Chief Scientist choose to use it, but the current intent is not to use this BAA for
future topics
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Fundamental Research BAA Solicitation:
HDTRA1-14-24-FRCWMD-BAA
39
• In effect March 2015-September 2024; posted at Grants.gov
• General Thrust Areas continuously OPEN for submissions; TRL1 – early TRL4
• Basic and exploratory Applied Research (6.1 & 6.2)
• Required: ~250-word abstract sent to applicable Thrust Area e-mail address detailed in
BAA; based on interest, a white paper may/may not be invited
• Majority of awards will be grants; other award types are permissible
• Basic Research Topics G1-G19 are OPEN for white paper submissions
• Responses to these topics must address only basic research
• These topics do NOT require abstract pre-coordination
• White Paper Deadline: February 1, 2017, by 11:59pm EST
• Invitation-Only Full Proposal Deadline: On/About April 24, 2017
• The majority of awards for Topics G1-G19 will be grants
• All applications MUST be submitted to Grants.gov using the application packages posted
with the opportunity
• Questions? Email: HDTRA1-FRCWMD-A@mail.mil
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Chem-Bio Technologies BAA Solicitation:
HDTRA1-17-S-0001
40
• Chemical Biological Technologies Department BAA, FY2017 Program Build
• Applied Research & Advanced Technology Development
• Seeks R&D projects with strong technical merit valuable to program requirements and goals
to improve military chemical and biological defense capabilities
• Phase II Proposal Receipt Deadline January 13, 2017 at 1400hrs EST (by invitation
only)
• Parallel DoD/Government ‘Service Call’ for Government Labs
• Questions? Email: dtra.belvoir.J9.mbx.CB-BAA@mail.mil
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Science and Technology New Initiatives BAA
Solicitation: HDTRA1-17-S-0002-BAA
41
• In effect November 2016-October 2021; posted at www.fbo.gov
• Efforts that advance technical state-of-the-art or increase knowledge and understanding of
overarching challenges for countering WMD; TRL2 – TRL6
• BAA will be conducted via a single phase: formal proposal submission
• Offerors may choose to pre-coordinate a white paper/quad chart as detailed in the BAA.
• Pre-coordination, while strongly encouraged, is not mandatory.
• Six R&D Technology Areas (TAs): Chemical/Biological; Counter WMD; Radiation/Nuclear;
Reach-back and Decision Support; Treaty Verification/Compliance; and Technology
Forecasting
• BAA continuously OPEN for submissions to the R&D TAs
• On a limited basis, Addendums to the BAA may be published that detail more specific
or urgent topics. Topics posted as Addendums are likely to have formal proposal
deadlines and will only be available for a limited time.
• Questions? Email: DTRAInnovation@mail.milThe forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to
purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
CWMD RD IDIQ Contracts
1. Counter WMD Weapons and Targets
2. Modeling and Simulation
3. Systems Engineering
4. Systems Survivability
5. WMD Physical Countermeasures
6. WMD Medical Countermeasures
7. Technical Nuclear Forensics
8. Nuclear Detection
9. Standoff Detection
10. Treaty and Verification Technologies
11. Sensor Platforms
42The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
10-year-Multi-Award $4B Ceiling
Capability to conduct research and development resulting in the delivery of data, hardware,
software, equipment and documentation for the 11 functional areas listed below:
UNCLASSIFIED
UNCLASSIFIED
CBD SBIR and STTR
43
• The Small Business Innovation Research (SBIR) and the Small Business Technology Transfer (STTR) programs are:
• Congressionally-mandated programs
• Established to fund R&D at small businesses
• Three-phased process
• Funded as a set-aside assessment of extramural R&D budget
• U.S. Small Business Administration (SBA) programmatic authority over Federal SBIR & STTR programs (Program Policy Directives)
• DoD has 12 SBIR/STTR Programs (3 Services & 9 ‘Components’)
• DTRA and Chem/Bio Defense (CBD) represent two separate programs; see: https://sbir.defensebusiness.org
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
DoD SBIR/STTR Solicitations
44
• Dates established by OSD Office of Small Business Programs; not all DoD Components
participate in each solicitation.
• CBD SBIR is participating in FY17.1 cycle and plans to participate in CBD STTR
FY17.C cycle
• A DoD Agency-wide announcement includes:
• DoD Instructions
• Service/Component-specific Instructions
• Topics
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Proposal submission
45
• Fundamental Research (Solicitation HDTRA1-14-24-FRCWMD-BAA), to include Basic
Research Topics, submitted to:
http://www.grants.gov
• Chem-Bio Technologies BAA (Solicitation HDTRA1-17-S-0001) and the Science and
Technology New Initiatives BAA (Solicitation HDTRA1-17-S-0002-BAA) submitted to:
https://www.dtrasubmission.net
• ALL DoD SBIR & STTR proposals (small businesses only) submitted to:
https://sbir.defensebusiness.org
Proposals only accepted via electronic submission
READ THE ANNOUNCEMENT INSTRUCTIONS!
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
UNCLASSIFIED
UNCLASSIFIED
Some Helpful Resources
46
• Business Opportunities at DTRA: http://www.dtra.mil/Contracts/BusinessOpportunities.aspx
http://www.dtra.mil/Research/Basic-and-Applied-Science/Research-Funding-Opportunities
• Doing Business with DoD: http://www.defense.gov/landing/contract_resources.aspx
• Guide to DoD Contracting Opportunities:
http://www.acq.osd.mil/dpap/cpic/cp/docs/Doing_Business_with_DoD_%282Jun14%29.pdf
• Federal Business Opportunities: https://www.fbo.gov/
• Grants.Gov: http://www.grants.gov
• DoD Office of Small Business Programs – Doing Business with the DoD:
http://www.acq.osd.mil/osbp/sb/dod.shtml
• DoD SBIR/STTR Program Information for Small Business:
https://sbir.defensebusiness.org
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services
PROGRAM POINTS OF CONTACT
• COL David Hammer, JPM MCS
david.p.hammer2.mil@mail.mil
• Dr. Edward Clayson, Deputy JPM MCS
Edward.t.Clayson.civ@mail.mil
• Dr. Erin Reichert, DTRA J9CB
erin.d.reichert.civ@mail.mil
The forecast data is for planning purposes, does not represent a pre-solicitation synopsis, does not constitute an invitation for bid or request for proposal, and is not a commitment by the government to purchase the desired products and services